Comparative Pharmacology
Head-to-head clinical analysis: BUTICAPS versus SODIUM BUTABARBITAL.
Peer-Reviewed Evidence
Head-to-head clinical analysis: BUTICAPS versus SODIUM BUTABARBITAL.
BUTICAPS vs SODIUM BUTABARBITAL
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Butalbital, a barbiturate, acts as a GABA-A receptor agonist, enhancing inhibitory neurotransmission in the CNS; acetaminophen inhibits cyclooxygenase (COX) activity and modulates endogenous cannabinoid receptors; caffeine is a non-selective adenosine receptor antagonist.
Barbiturate that enhances GABA-A receptor activity, increasing chloride ion conductance and causing CNS depression.
500 mg orally every 8 hours.
50-100 mg orally or intramuscularly 3-4 times daily as a sedative; 100-200 mg orally or intramuscularly for preoperative sedation.
None Documented
None Documented
3-5 hours (prolonged in renal impairment; dose adjustment required for CrCl <30 mL/min)
Terminal elimination half-life 40-60 hours in adults; prolonged in hepatic impairment and elderly.
Renal (90% as unchanged drug), biliary/fecal (10%)
Renal excretion of unchanged drug and metabolites; approximately 30-50% as unchanged drug in urine. Minor fecal elimination (<5%).
Category C
Category C
Barbiturate
Barbiturate